Low blood eosinophil counts are not always a reliable marker of clinical response to mepolizumab in severe asthma

J Allergy Clin Immunol Pract. 2018 Nov-Dec;6(6):2151-2153. doi: 10.1016/j.jaip.2018.04.014. Epub 2018 Apr 30.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Asthma / drug therapy*
  • Biomarkers, Pharmacological
  • Blood Cells / immunology*
  • Disease Progression
  • Eosinophils / immunology*
  • Female
  • Humans
  • Immunotherapy / methods*
  • Middle Aged
  • Severity of Illness Index

Substances

  • Antibodies, Monoclonal, Humanized
  • Biomarkers, Pharmacological
  • mepolizumab